Clarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at the Androgen Society 4th Annual Meeting
April 19, 2022 09:05 ET
|
Clarus Therapeutics Holdings, Inc.
JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions NORTHBROOK, Ill., April 19, 2022 ...
Clarus Therapeutics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results
March 30, 2022 16:05 ET
|
Clarus Therapeutics Holdings, Inc.
2021 net revenue increased 119% year-over-year to $14.0 million Fourth quarter 2021 net revenue increased 88% year-over-year to $4.6 million Fourth quarter 2021 total prescription growth for...
Clarus Therapeutics to Report Fourth Quarter and Full Year 2021 Financial and Operating Results
March 29, 2022 16:05 ET
|
Clarus Therapeutics Holdings, Inc.
NORTHBROOK, Ill., March 29, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (“Clarus”) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by...
Clarus Announces Strategic Partnerships for JATENZO® (testosterone undecanoate) with Vault Health and AssistRx – Leaders in Providing Healthcare Services to Patients
February 24, 2022 08:00 ET
|
Clarus Therapeutics Holdings, Inc.
JATENZO is the first and only FDA-approved oral softgel capsule for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions New offerings...
Clarus Therapeutics Appoints Dr. Zhanna Jumadilova as Chief Clinical Development Officer
January 18, 2022 09:05 ET
|
Clarus Therapeutics Holdings, Inc.
Dr. Jumadilova most recently led clinical development programs at Insmed and Pfizer and has nearly 30 years of combined pharmaceutical and biotech experience NORTHBROOK, Ill., Jan. 18, 2022 (GLOBE...
Clarus Therapeutics Announces Commercial Launch and Availability of JATENZO® (testosterone undecanoate) capsules, CIII for the Treatment of Hypogonadism
February 10, 2020 08:00 ET
|
Clarus Therapeutics, Inc.
First and only FDA-approved oral treatment of its kind for testosterone deficiency1,2 NORTHBROOK, Ill., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Clarus Therapeutics, Inc. today announced that JATENZO®...
Clarus Capital Limited Appoints Alternative Energy Veteran John Carrington to Board
July 02, 2010 13:40 ET
|
Clarus Capital Limited
HONG KONG--(Marketwire - July 2, 2010) - Clarus Capital Limited ("Clarus" or the "Company") is pleased to advise of the appointment today of Mr. John E. Carrington to its Board of Directors.
...
Qorvis Nominated for 2009 "Midsize PR Agency of the Year" by PRWeek
January 12, 2009 12:16 ET
|
Qorvis Communications
WASHINGTON, DC--(Marketwire - January 12, 2009) - Qorvis
Communications announced today that it has been named a finalist by
PRWeek for the category of Midsize PR Agency of the Year
2009.
"Being...